Synonyms: BMS986172 | compound 12 [PMID: 37724542]
Compound class:
Synthetic organic
Comment: BMS-986172 acts as a monoacylglycerol O-acyltransferase 2 (MGAT2) inhibitor [1]. MGAT2 inhibitors are candidates for the treatment of diabetes, obesity and associated metabolic disorders.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
BMS-986172 is an early stage clinical lead for the treatment of obesity. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04926051 | A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption | Phase 1 Interventional | Bristol-Myers Squibb |